Evolving Issues in the Treatment of Depression
Ole Köhler‐forsberg, Cristina Cusin, Andrew A. Nierenberg
JAMA May 24, 2019 DOI: 10.1001/jama.2019.4990 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Exercise Mediterranean diet and structured dietary support Ketamine Esketamine Anti-inflammatory drugs Brexanolone Psilocybin |
| Topics | Depression Ketamine Psilocybin |
| Keywords | Depression economics Drug Mediterranean diet Intensive care medicine Pharmacology Hallucinogen Cognition |
| Citations | 18 |
| Key findings | Multiple nonpharmacological and drug therapies, including exercise, Mediterranean diet, ketamine, and psilocybin, have documented benefits for major depressive disorder. |
Abstract
This Viewpoint discusses recent evidence documenting benefits of nonpharmacological and drug therapies for major depressive disorder including exercise, Mediterranean diet and structured dietary support, ketamine and esketamine, anti-inflammatory drugs, brexanolone, and psilocybin.
Comparable studies
Other narrative reviews on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression | 2021 | Review | |
| Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Registered clinical trials on clinicaltrials.gov evaluating psychedelics for... | 2021 | Review | n = 70 |
| Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review | 2020 | Review | |
| From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders | 2021 | Review |